SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Benjamin Franklin

PatientBenjamin Franklin
Date of birth1950-01-17
IdentifiersMRN HR-EN004-SYN; SSN (made up) 000-04-3318
Document date2026-03-30
AuthorLydia Penhallow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week gout and blood pressure review; urology consultation today. [S]

History of Present Illness

Mr. Franklin returns four weeks after starting allopurinol 100 mg and colchicine 0.6 mg daily and changing hydrochlorothiazide to losartan 50 mg. He has had no gout flare, no rash, and no diarrhea. His home blood pressure averages 136/80. He still has an interrupted stream, pain at the end of voiding, and pink urine after car journeys, and he gets up three times a night. He takes acetaminophen for the bladder pain about twice a week and no ibuprofen. He is drinking more water, about 1.5 L a day, and has cut back to one glass of wine with dinner. He saw the urologist this morning. [S]

ElementDetail
GoutNo flare since starting allopurinol and colchicine
Medication toleranceNo rash, diarrhea, or muscle aches
Home blood pressureAverage 136/80 mmHg on losartan
Urinary symptomsInterrupted stream, terminal pain, pink urine after car journeys; nocturia three times
Fluids and dietAbout 1.5 L of water a day; one glass of wine with dinner

Review of Systems

SystemResultFinding
MusculoskeletalNegativeNo joint pain or swelling
GenitourinaryPositiveInterrupted stream, terminal dysuria, intermittent pink urine, nocturia three times
IntegumentaryNegativeNo rash or itching on allopurinol
GastrointestinalNegativeNo diarrhea or nausea on colchicine
NeurologicalNegativeNo dizziness on standing

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2019-05-06 to 2026-03-02stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02activeS
Allopurinol 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02 to 2026-03-30completedS
Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth dailyTwo tablets by mouth dailyOral route2026-03-30 to 2026-05-18completedS
Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxisOne tablet by mouth dailyOral route2026-03-02 to 2026-09-14completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route2026-03-02activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgeryOne capsule by mouth at bedtimeOral route2026-03-30 to 2026-04-20completedS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-30Body height175cmS
2026-03-30Body weight95.4kgS
2026-03-30Body mass index (BMI) [Ratio]31.2kg/m2S
2026-03-30Systolic blood pressure138mm[Hg]S
2026-03-30Diastolic blood pressure80mm[Hg]S
2026-03-30Heart rate70/minS
2026-03-30Respiratory rate16/minS
2026-03-30Body temperature36.6CelS
2026-03-30Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-30Urate [Mass/volume] in Serum or Plasma7.6mg/dL3.5-7.2 mg/dLHighS
2026-03-30Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-30Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-03-30Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-03-30Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL8-23 mg/dLNormalS
2026-03-30Creatinine [Mass/volume] in Serum or Plasma1.34mg/dL0.74-1.35 mg/dLNormalS
2026-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-30Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-03-30US Urinary bladder Volume post void160mL<=100 mLHighS
2026-03-30Maximum Urine flow by Uroflowmetry8.5mL/s>=10 mL/sLowS
2026-03-30International Prostate Symptom Score [IPSS]16{score}S

Physical Exam

Vital signs recorded on 2026-03-30; see the Vital Signs section. [S]

SystemFinding
GeneralWell, comfortable
JointsNo synovitis; no tophi; right first toe joint normal
AbdomenMild suprapubic tenderness; bladder not palpable
CardiovascularRegular rhythm; no edema
SkinNo rash

Problems

ProblemClinical statusVerificationCodeProvenance
Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented goutactiveconfirmed M1A.0710S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D).
Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stoneresolvedconfirmed N21.0S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known.
Chronic kidney disease stage G3a A1activeconfirmed N18.31S — Synthetic diagnosis; no measure of kidney function from his lifetime exists.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis; no blood pressure from his lifetime exists.
Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resectionactiveconfirmed N40.1S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySerum urateEvery 2 to 5 weeks while titrating; every 6 months once at targetCompleted today7.6 mg/dL four weeks after starting allopurinol 100 mg; dose increased
Medication safetyAllopurinol hypersensitivity and colchicine toleranceEvery visit while titratingCompleted todayNo rash, fever, diarrhea, or muscle symptoms
LaboratoryHLA-B*58:01 before allopurinolOnce, only in Southeast Asian or African American patientsNot indicatedNot of Southeast Asian or African ancestry
Medication safetyFlare prophylaxis3 to 6 months after starting urate-lowering therapyCompleted todayColchicine 0.6 mg daily, week 4
LaboratoryPotassium and creatinine 2 to 4 weeks after starting an ARBOnce after starting or titratingCompleted todayPotassium 4.4 mmol/L, creatinine 1.34 mg/dL, eGFR 55, four weeks after starting losartan
ExaminationOffice and home blood pressureEvery visitCompleted today138/80 mmHg in the office; home average 136/80
Medication safetyMedication review for NSAIDs and dose adjustment for kidney functionEvery visitCompleted todayNo NSAIDs; allopurinol and colchicine doses suit eGFR 55
SurveyIPSSBaseline and every follow-up visitCompleted today16, moderate
ExaminationUroflowmetry and post-void residualBefore a procedure or when obstruction is suspectedCompleted todayMaximum flow 8.5 mL/s; residual 160 mL
ReferralUrology evaluation of the bladder stone and hematuriaAt diagnosisCompleted todaySeen today; cystoscopy shows no tumor; surgery booked
LaboratoryPSAOnly if it would change managementNot indicatedAge 76; it would not change the planned surgery, and resected tissue will be examined
Self-managementFluid intake for stone preventionEvery visitCompleted todayAbout 1.5 L a day; goal 2.5 to 3 L
Self-managementDiet and alcohol for goutEvery visitCompleted todayWine cut to one glass with dinner; fewer rich meals

Goal progress:

Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)

Follow-up: Surgery in three weeks. Review four weeks after surgery with serum urate, a metabolic panel, urine tests, and a 24-hour urine collection. Next scheduled visit 2026-05-18: review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluation. [S]